98%
921
2 minutes
20
Objective: To determine prognostic indicators for morbidity and mortality in patients with fulminant hepatic failure.
Design: Observational study.
Place And Duration Of Study: Department of Gastroenterology and Hepatology, Shaikh Zayed Postgraduate Medical Institute, Lahore, from April 2003 to June 2005.
Patients And Methods: Forty five patients with confirmed diagnosis of fulminant hepatic failure were included in this study. They were investigated for acute viral serology, complete blood count, liver function tests, renal function tests, serum electrolytes, arterial blood gases, initially daily and then on alternate days. Patients were followed in high dependency/ICU at the Shaikh Zayed Postgraduate Medical Institute. Data were analyzed by logistic regression analysis to identify predictors of mortality and morbidity.
Results: Of the 45 subjects, 31 were males and 14 females. Twenty four patients were positive for acute hepatitis E. Twenty patients recovered fully, whereas 25 died with mortality rate of 55.6 %. Variables i.e. presence of non-A non-B viral hepatitis, serum creatinine > 2.0 mg/dl, serum phosphate > 3.5 mg/dl and sepsis were found to have significant association with mortality on linear correlation. Only serum creatinine more than 2.0 mg/dl, serum phosphate > 3.5 mg/dl and development of sepsis were found to predict the outcome after multivariate analysis.
Conclusion: Patients with serum creatinine > 2.0 mg/dl, serum phosphate > 3.5 mg/dl and sepsis showed adverse prognosis for survival.
Download full-text PDF |
Source |
---|
Front Oncol
August 2025
Hunan Cancer Hospital, The Affiliated Cancer Hospital, Xiangya School of Medicine, Central South University, Changsha, Hunan, China.
Tislelizumab, an anti-PD-1 monoclonal antibody, is associated with immune-related hepatitis in 1.8% of cases, but reports of acute liver failure (ALF) remain exceedingly rare. We present a case of fulminant hepatitis and ALF following Tislelizumab therapy in a 55-year-old woman with locally advanced cervical adenocarcinoma.
View Article and Find Full Text PDFFront Vet Sci
August 2025
Faculty of Health Sciences, Universidad Científica del Sur, Lima, Peru.
Background: Yellow fever virus (YFV) remains a re-emerging zoonotic threat in South America. While epizootics in free-ranging spp. are well-documented, little is known about YFV infection in other Neotropical non-human primates (NHPs), particularly in captive settings.
View Article and Find Full Text PDFCureus
August 2025
Paediatrics, Farooq Hospital, West Wood Branch, Lahore, Lahore, PAK.
Hepatitis A virus (HAV) typically causes a self-limiting illness in children. Rarely, it can progress to fulminant hepatic failure (FHF), and even less commonly, may be followed by features suggestive of autoimmune hepatitis (AIH). The diagnostic overlap can be particularly challenging in tropical regions, where endemic infections such as dengue and malaria may present with similar clinical features.
View Article and Find Full Text PDFS D Med
July 2025
Sanford USD Medical Center, Sioux Falls, South Dakota.
Drug-induced liver injury (DILI) is a leading cause of acute liver failure in the U.S., though allopurinol and colchicine have not been widely associated with fulminant hepatic failure.
View Article and Find Full Text PDFTransplant Proc
August 2025
Florya VM Medical Park Application and Research Hospital, Organ Transplantation Center, Dr. Istanbul Aydın University, Istanbul, Turkey.
Objective: Liver transplantation is currently the most treatment for fulminant hepatitis, end-stage liver failure, hepatocellular carcinoma, and liver-originated metabolic diseases in children. With technological advances, improvements in surgical techniques and immunosuppressive therapy protocols have increased 1-year survival rates to 80%-90%. Our center successfully performs both living donor and cadaveric liver transplants in children.
View Article and Find Full Text PDF